CUSIP 478160DJ0BondJNJQ4 2025
225 reported transactions
| # | Date | Insider | Title | Type | Shares | Price | Value | Held After | Filing |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M · Option Exercise | 10.0K | $115.67 | $1.16M | 124.3K | SEC |
| 2 | Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | S · Sell | 10.0K | $241.15 | $2.41M | 114.3K | SEC |
| 3 | Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M · Option Exercise | 10.0K |
See the full Form 4 transaction history for Johnson & Johnson.
Unlock all transactions| $0.00 |
| $0 |
| 33.0K |
| SEC |
| 4 | Jun 9, 2026 | Woods Eugene A. | Director | A · Grant | 161 | $232.79 | $37.5K | 6.4K | SEC |
| 5 | Jun 9, 2026 | Pinto Daniel E | Director | A · Grant | 134 | $232.79 | $31.3K | 2.3K | SEC |
| 6 | Jun 9, 2026 | Hewson Marillyn A | Director | A · Grant | 215 | $232.79 | $50.0K | 15.8K | SEC |
| 7 | May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | M · Option Exercise | 25.3K | $0.00 | $0 | 35.9K | SEC |
| 8 | May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | F · Tax | 11.0K | $229.85 | $2.53M | 24.9K | SEC |
| 9 | May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | M · Option Exercise | 25.3K | $0.00 | $0 | 0 | SEC |
| 10 | Apr 23, 2026 | Woods Eugene A. | Director | A · Grant | 975 | $0.00 | $0 | 6.2K | SEC |